ArticleNPJ vaccines2023
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.
Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Maximizing impact: the power of early HPV vaccination for long-term protection-lessons from a systematic review and meta-regression analysis.Journal of public health (Oxford, England) · 2026Pooled it
- Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Human vaccines & immunotherapeutics · 2026Review
- Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention.Antibodies (Basel, Switzerland) · 2026Review
- Review
- Differential Host Gene Expression Associated with Non-Research square · 2026Article
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection.NPJ vaccines · 2026Article
- HPV vaccination associates withFrontiers in microbiology · 2026Article
- Immune Responses to Human Papillomavirus After Infection and Vaccination.Current topics in microbiology and immunology · 2026Review
- Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial.NPJ vaccines · 2025Article
- Molecular Insights into HPV-Driven Head and Neck Cancers: From Viral Oncoproteins to Precision Therapeutics.Viruses · 2025Review
- Evaluation of Anti-HPV18 Antibody Titers Preceding an Incident Cervical HPV18/45 Infection.Vaccines · 2025Article
- Recent advances in therapeutic cancer vaccines.Nature reviews. Cancer · 2025Review
- Scientific approaches to defining HPV vaccine-induced protective immunity.International journal of cancer · 2025Review
- Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.Nature communications · 2025Article
- AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells.Frontiers in immunology · 2025Article
- Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.NPJ vaccines · 2024Article
- Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.Frontiers in immunology · 2024Review
- Current status and future directions for the development of human papillomavirus vaccines.Frontiers in immunology · 2024Review
- The future of cancer immunotherapy: DNA vaccines leading the way.Medical oncology (Northwood, London, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gardasil® (Merck) and Cervarix® (GlaxoSmithKline) both provide protection against infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18), that account for around 70% of cervical cancers. Both vaccines have been shown to induce high levels of neutralizing antibodies and are known to protect against progression beyond cervical intraepithelial neoplasia grade 2 (CIN2+), although Cervarix® has been linked to enhanced protection from progression. However, beyond the transmission-blocking activity of neutralizing antibodies against HPV, no clear correlate of protection has been defined that may explain persistent control and clearance elicited by HPV vaccines. Beyond blocking, antibodies contribute to antiviral activity via the recruitment of the cytotoxic and opsonophagocytic power of the immune system. Thus, here, we used systems serology to comprehensively profile Gardasil®- and Cervarix®- induced antibody subclass, isotype, Fc-receptor binding, and Fc-effector functions against the HPV16 and HPV18 major capsid protein (L1). Overall, both vaccines induced robust functional humoral immune responses against both HPV16 and HPV18. However, Cervarix® elicited higher IgG3 and antibody-dependent complement activating responses, and an overall more coordinated response between HPV16 and 18 compared to Gardasil®, potentially related to the distinct adjuvants delivered with the vaccines. Thus, these data point to robust Fc-effector functions induced by both Gardasil® and Cervarix®, albeit with enhanced coordination observed with Cervarix®, potentially underlying immunological correlates of post-infection control of HPV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.